Jowita Fiszer

Jowita Fiszer

Auto-generated profile, based on publicly available information

Jowita Fiszer

Department of Endocrinology and Internal Medicine Medical University of Gdansk Gdańsk Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2025 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PKPiotr Kmieć
Piotr Kmieć
DODominika Okroj
Dominika Okroj
MZMałgorzata Zdrojewska
Małgorzata Zdrojewska
JFJowita Fiszer
Jowita Fiszer
SZSonia Zembrzuska
Sonia Zembrzuska
RŚRenata Świątkowska-Stodulska
Renata Świątkowska-Stodulska
Screening for primary aldosteronism (PA) remains exceedingly low, despite the fact that the disorder contributes to or underlies hypertension (HT) in as many as 20% of unselected patients. Conventionally, withdrawal of medications interfering with the renin‒angiotensin‒aldosterone system (RAAS) has been recommended before PA work‐up. Previous research showed that combining objective thresholds and 2‐day cosyntropin suppression was highly accurate in diagnosing PA among HT patients off interfering drugs. Here, we present the protocol of a study designed to generate and temporally validate aldosterone‐to‐renin ratio (ARR) thresholds following overnight cosyntropin suppression in PA screening on interfering medications. We hypothesize that overnight cosyntropin suppression with 1 mg dexamethasone will result in 25% higher diagnostic interpretability compared to conventional ARR testing. This single‐center study consists of a development and confirmation cohort (both n = 80). Patients with an adrenal incidentaloma are enrolled in a 1‐day clinic. Aldosterone‐to‐renin ratios (ARRs) are determined before and after overnight intake of 1 mg dexamethasone (DXM) on, partially off, and off medications interfering with the RAAS. Emphasis on screening and limitation of PA confirmatory (suppression) tests have been included in the current Endocrine Society guideline on PA due to low evidence of benefits of the latter in diagnosing the disorder. In light of poor PA screening rates, the ODEPRASC study may provide a rationale for an optimized diagnostic approach. Trial Registration : ClinicalTrials.gov identifier: NCT06740838.